GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:014001411 | Liver | HCC | mitotic nuclear division | 174/7958 | 287/18723 | 3.74e-10 | 1.23e-08 | 174 |
GO:0000070 | Liver | HCC | mitotic sister chromatid segregation | 110/7958 | 168/18723 | 1.42e-09 | 4.25e-08 | 110 |
GO:00008191 | Liver | HCC | sister chromatid segregation | 128/7958 | 202/18723 | 1.59e-09 | 4.73e-08 | 128 |
GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
GO:0098813 | Liver | HCC | nuclear chromosome segregation | 157/7958 | 281/18723 | 3.82e-06 | 4.95e-05 | 157 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:00070624 | Liver | HCC | sister chromatid cohesion | 38/7958 | 62/18723 | 2.18e-03 | 1.09e-02 | 38 |
GO:014001416 | Thyroid | ATC | mitotic nuclear division | 171/6293 | 287/18723 | 1.13e-19 | 1.66e-17 | 171 |
GO:000007013 | Thyroid | ATC | mitotic sister chromatid segregation | 108/6293 | 168/18723 | 3.53e-16 | 2.90e-14 | 108 |
GO:000081913 | Thyroid | ATC | sister chromatid segregation | 122/6293 | 202/18723 | 4.71e-15 | 3.17e-13 | 122 |
GO:000705913 | Thyroid | ATC | chromosome segregation | 183/6293 | 346/18723 | 8.03e-14 | 4.23e-12 | 183 |
GO:009881312 | Thyroid | ATC | nuclear chromosome segregation | 145/6293 | 281/18723 | 3.06e-10 | 8.61e-09 | 145 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
GO:000028011 | Thyroid | ATC | nuclear division | 207/6293 | 439/18723 | 1.98e-09 | 4.80e-08 | 207 |
GO:000706213 | Thyroid | ATC | sister chromatid cohesion | 35/6293 | 62/18723 | 1.81e-04 | 1.23e-03 | 35 |
GO:0070601 | Thyroid | ATC | centromeric sister chromatid cohesion | 9/6293 | 11/18723 | 1.46e-03 | 7.47e-03 | 9 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SGO2 | SNV | Missense_Mutation | | c.1453N>A | p.Glu485Lys | p.E485K | Q562F6 | protein_coding | tolerated(0.16) | benign(0.033) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SGO2 | SNV | Missense_Mutation | | c.2024G>C | p.Arg675Thr | p.R675T | Q562F6 | protein_coding | tolerated(0.6) | benign(0.022) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SGO2 | SNV | Missense_Mutation | | c.863N>G | p.Asp288Gly | p.D288G | Q562F6 | protein_coding | tolerated(0.1) | possibly_damaging(0.536) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
SGO2 | insertion | Frame_Shift_Ins | novel | c.2955dupA | p.Arg986ThrfsTer2 | p.R986Tfs*2 | Q562F6 | protein_coding | | | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SGO2 | SNV | Missense_Mutation | | c.3445N>C | p.Asp1149His | p.D1149H | Q562F6 | protein_coding | tolerated(0.06) | possibly_damaging(0.874) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
SGO2 | SNV | Missense_Mutation | | c.3706G>C | p.Glu1236Gln | p.E1236Q | Q562F6 | protein_coding | deleterious(0.03) | probably_damaging(0.913) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SGO2 | SNV | Missense_Mutation | | c.1900G>C | p.Asp634His | p.D634H | Q562F6 | protein_coding | deleterious(0.05) | benign(0.037) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SGO2 | SNV | Missense_Mutation | | c.2674N>T | p.Asp892Tyr | p.D892Y | Q562F6 | protein_coding | tolerated(0.08) | probably_damaging(0.943) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SGO2 | SNV | Missense_Mutation | | c.3431N>T | p.Ser1144Leu | p.S1144L | Q562F6 | protein_coding | tolerated(0.09) | benign(0.039) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
SGO2 | SNV | Missense_Mutation | novel | c.3240N>C | p.Lys1080Asn | p.K1080N | Q562F6 | protein_coding | deleterious(0.05) | probably_damaging(0.92) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |